Patients with severe asthma report fatigue, sleep disturbances, physical inactivity, and reduced work productivity as some of ...

FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation -- Expect to initia ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

Using nasal swabs to identify a child’s asthma subtype may lead to more precise medication prescribing and development of ...

Getting prior authorization for medications can be a struggle in allergy and asthma care, but creating templates and paying ...

Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...